NCT06528210 2025-09-23
Pembrolizumab With Androgen Deprivation Therapy and Radiotherapy for the Treatment of Patients With High Risk Localized Prostate Cancer
OHSU Knight Cancer Institute
Phase 2 Withdrawn
OHSU Knight Cancer Institute
University of Nebraska
CHU de Quebec-Universite Laval
Mayo Clinic
University of Kansas Medical Center
OHSU Knight Cancer Institute